X-154379754-GC-GCC
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000117.3(EMD):c.153dupC(p.Ser52GlnfsTer9) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000914 in 1,093,711 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000117.3 frameshift
Scores
Clinical Significance
Conservation
Publications
- X-linked Emery-Dreifuss muscular dystrophyInheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- heart conduction diseaseInheritance: XL Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| EMD | NM_000117.3 | c.153dupC | p.Ser52GlnfsTer9 | frameshift_variant | Exon 2 of 6 | ENST00000369842.9 | NP_000108.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| EMD | ENST00000369842.9 | c.153dupC | p.Ser52GlnfsTer9 | frameshift_variant | Exon 2 of 6 | 1 | NM_000117.3 | ENSP00000358857.4 |
Frequencies
GnomAD3 genomes Cov.: 25
GnomAD4 exome AF: 9.14e-7 AC: 1AN: 1093711Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 360299 show subpopulations
GnomAD4 genome Cov.: 25
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. Based on the information below, we consider this variant very likely pathogenic. The c.153dupC EMD variant, located on exon 2, results from a duplication of cysteine at position 153, causing a translational frameshift with a predicted premature stop codon. This variant was identified in a 9 year old boy with a clinical diagnosis of limb girdle muscular dystrophy, with absence of emerin on IHC staiining of skeletal muscle biopsy tissue (Ura et al., 2007). This patient had a normal echocardiogram. Brown and colleagues (Brown et al., 2011) studied 225 participants referred for genetic screening following a clinical diagnosis of EDMD, limb-girdle muscular dystrophy, Becker muscular dystrophy or FSHD. FHL1, SYNE1 and SYNE2 mutations were not screened, as the screening programme predated linkage of these genes to the EDMD phenotype. They reported eight novel mutations including six frameshift mutations (p.D9GfsX24, p.F39SfsX17, p.R45KfsX16, p.F190YfsX19, p.R203PfsX34 and p.R204PfsX7) and two non-sense mutations (p.S143X and p.W200X) Brown et al. also identified exon 2 as a hot spot for mutations in the EMD gene. The three most common mutations identified in exon 2 were at codon 51 resulting in p.S52AfsX13 (4 hits; stop at codon 64) and p.Y34X (3 hits). Four of the 18 (22%) probands had mutations in exon 2, of which two are novel but with one also targeting residue S52. Frameshift mutations in the EMD gene have been previously shown to allow modified emerin expression, suggest the shortest length required for protein expression is 208 residues, which is 94% (208/221) of the nucleoplasmic domain length, as shown by the in vivo expression of the p.P169RfsX40 mutation. From this, we can predict that three of our novel mutations (p.F190YfsX19, p.R203PfsX34 and p.R204PfsX7) will express truncated forms of erroneous protein, with the remaining mutations preventing protein expression. There is no variation at codon 52 listed in the NHLBI Exome Sequencing Project dataset, which currently includes variant calls on ~6,500 Caucasian and African American individuals (as of 8/1/13). -
X-linked Emery-Dreifuss muscular dystrophy Pathogenic:1
This sequence change creates a premature translational stop signal (p.Ser52Glnfs*9) in the EMD gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EMD are known to be pathogenic (PMID: 24365856). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy (PMID: 17620497, 21697856). This variant is also known as c.153_154insC. ClinVar contains an entry for this variant (Variation ID: 234991). For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The c.153dupC pathogenic mutation, located in coding exon 2 of the EMD gene, results from a duplication of cysteine at position 153, causing a translational frameshift with a predicted premature stop codon. In one study, this alteration was identified in a 9 year old boy with clinical diagnosis of limb girdle muscular dystrophy (LGMD), who had absence of emerin on immunohistochemical staining of skeletal muscle biopsy tissue. Clinical features at age 9 included Gowers sign, waddling gait, proximal dominant limb muscle weakness and atrophy, transient sinus arrhythmia on electrocardiogram, but no joint contractures and a normal echocardiogram (Ura etal. Arch. Neurol. 2007;64:1038-1041). This alteration was also identified in a series of patients referred for genetic testing due to a suspected diagnosis of Emery-Dreiffuss muscular dystrophy (EDMD). Authors identify exon 2 as a hot spot for mutations in the EMD gene (Brown etal. J. Hum. Genet. 2011;56:589-594). In addition, alterations causing a translational frameshift are typically deleterious in nature (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). Based on available evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at